470results about How to "Good blood pressure" patented technology

The invention provides a monitor for measuring blood pressure and other vital signs from a patient without using a cuff. The monitor features a housing with a first surface that, in turn, supports a first sensor. The first sensor features: i) an optical system with one or more light sources (e.g., LEDs or laser diodes) that generate optical radiation, and a photodetector oriented to collect radiation after it irradiates the patient and in response generate an optical signal; and ii) a first electrode. A second sensor features a second electrode paired with the first electrode that collects an electrical signal from the patient. A microprocessor in electrical communication with the first and second sensor receives the optical and electrical signals and processes them with an algorithm to determine systolic and diastolic blood pressure.

A method and device for delivering and monitoring baroreflex and drug therapy to manage hypertension. The method includes providing an implanted an implanted medical device configured to automatically detect drug-related effects on the autonomic nervous system including the steps of measuring a physiologic status of the autonomic nervous system at desired intervals, logging the physiologic status of the autonomic nervous system at desired intervals, monitoring the measured and logged physiologic status of the autonomic nervous system for any changes and correlating the changes to a corresponding drug administration time. The device includes an implanted baroreflex activation device capable of administering one or more hypertension treatment drugs including a controller that activates and adjusts therapy delivery, a baroreflex activation therapy delivery device, a drug therapy delivery device and a device that senses physiologic parameters.

A permanent thrombus and plaque filtering stent blocks and / or filters potential emboli in patients undergoing intravascular treatment and / or stent implantation. The stent has a plurality of movable magnetic or ultrasonic agitating elements attached thereto, which when remotely activated move, vibrate or rotate to break up the thrombus, plaque or tissue debris.

One method for diagnosing a cardiovascular-related condition in a breathing person comprises interfacing a valve system to the person's airway. The valve system is configured to decrease or prevent respiratory gas flow to the person's lungs during at least a portion of an inhalation event. The person is permitted to inhale and exhale through the valve system. During inhalation, the valve system functions to produce a vacuum within the thorax to increase blood flow back to the right heart of the person, thereby increasing blood circulation and blood pressure. Further, at least one physiological parameter is measured while the person inhales and exhales through the valve system. The measured parameter is evaluated to diagnose a cardiovascular condition.

A radiosurgical method for treating cardiorenal disease of a patient, the method including directing radiosurgery radiation from outside the patient towards one or more target treatment regions encompassing sympathetic ganglia of the patient so as to inhibit the cardiorenal disease. In an exemplary embodiment, the method further includes acquiring three dimensional planning image data encompassing the first and second renal arteries, planning an ionizing radiation treatment of first and second target regions using the three dimensional planning image data so as to mitigate the hypertension, the first and second target regions encompassing neural tissue of or proximate to the first and second renal arteries, respectively, and remodeling the target regions by directing the planned radiation from outside the body toward the target regions.

The invention relates to the use of angiotensin II receptor antagonists for treating people in whom type 2 diabetes mellitus has been diagnosed or who are suspected of prediabetes, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure.

A method and apparatus for stimulation of a baroreflex system of a patient is provided. A method comprises establishing a therapy regimen including at least one pulse which includes at least two phases. Each phase has a polarity which is different than that of the other phase. The baroreflex system of the patient is activated with at least one baroreflex activation device which is responsive to the therapy regimen.

A pressure and a vision regulation method and device for irrigation of a body cavity (1), in which method an inflow liquid pump (2) pressurizes the irrigation liquid in a feed line (13) and in which an outflow device (3) or an external suction source (20) drains the irrigation liquid from the body cavity (1) through a tubing (16) into a waste container (17) and in which a control unit (4) controls either the inflow liquid pump (2) only or both the inflow liquid pump (2) and the outflow device (3) depending on an inflow irrigation liquid pressure from a pressure sensor (5), where the first control unit (4) compares the inflow irrigation liquid pressure and flow with pressures calculated to correspond to pressure in the body cavity for the respective flow for a nominal surgical site and that a matching between the calculated values and the inflow irrigation liquid pressures is made by altering the effect of either the inflow liquid pump (2) only or the inflow liquid pump (2) and / or the outflow device (3) and / or the shut off valve. The above-mentioned pressure registration method and the device for irrigation of a body cavity is combined with an method for detecting blood cells, red blood cells, haemoglobin and / or debris in liquid coming from a surgical site so an automatically control and rinsing system is achieved keeping a clear vision in the viewing area of the operational site.

Dairy or non-diary based fortified carbonated beverage solutions that supply essential nutrients in the human diet. The solution contains per 354 ml, calcium, magnesium and potassium ions in the form of salts and optionally vitamins A, D, C, lutein, zeaxanthin and folic acid in specified amounts to provide dietary supplementation. Sweeteners, stabilizers, flavors and carbonation can also be added to enhance flavor, taste, mouth-feel, ingredient solubilization and product appearance. A method of making the beverages is also described. A method of using carbonation to reduce bacterial counts and reduce degradation of essential nutrients in milk-based beverages with or without pasteurization is also disclosed.

A method is provided, comprising: (1) making a transapical puncture into a left ventricle of the heart; (2) making a transseptal fenestration in the heart; (3) delivering a prosthetic valve via the transapical puncture and implanting the prosthetic valve at a mitral valve of the heart; and (4) subsequently to delivering the prosthetic valve and making the transseptal fenestration, closing the transapical puncture. Other embodiments are also described.

A method is provided for resuscitating a patient from cardiac arrest. This may be done by (a) performing chest compressions for a first period of time at a depth of between about 1.5 to about 3 inches, and (b) ceasing chest compressions for a second period of time. Steps (a) and (b) may be repeated at least two times in order to prevent reperfusion injury after cardiac arrest.

Methods and devices for reducing ventricle filling volume are disclosed. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to reduce ventricle filling volume or even blood pressure. When the heart is stimulated in a consistent way to reduce blood pressure, the cardiovascular system may over time adapt to the stimulation and revert back to the higher blood pressure. In some embodiments, the stimulation pattern may be configured to be inconsistent such that the adaptation response of the heart is reduced or even prevented. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to cause at least a portion of an atrial contraction to occur while the atrioventricular valve is closed. Such an atrial contraction may deposit less blood into the corresponding ventricle than when the atrioventricular valve is opened throughout an atrial contraction.

A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood flow rate through the shunt device of at least 5 ml / min after the implantation. The blood flow rate could be controlled either via an open loop or a closed loop control means. The shunt device could also be a self-adjustable shunt device to self-adjust its structure to control the blood flow rate through its lumen. Based on the effects of the shunt device to the respiratory, cardiac and circulatory system, the implantable shunt device could be beneficial as a therapy to patients with problems or conditions related to these systems.

A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a calcium channel blocker is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred calcium channel blockers are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9alpha,11alpha-substituted epoxy moiety. A preferred combination therapy includes the calcium channel blocker verapamil HCl (Benzenacetonitrile, (±)-alpha[3[[2-(3,4-dimethoxyphenyl) ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)hydrochloride) and the aldosterone receptor antagonist epoxymexrenone.

The invention relates to multi-functional composite oligopeptide nutrition powder which comprises raw materials with parts by weight: 1-2 parts of fish skin collagen oligopeptide, 0.5-2 parts of corn oligopeptide, 2-3 parts of beef bone oligopeptide, 0.2-1 part of sea cucumber oligopeptide, 0.2-1 part of oyster oligopeptide, 0.5-2 parts of walnut oligopeptide, 0.5-2 parts of soybean oligopeptide and 0.5-1 part of auxiliary materials. The multi-functional composite oligopeptide nutrition powder has functions of adjusting immunity, relieving fatigue, preventing cancer, improving elderly memory function, resisting presenile dementia, resisting oxidation, dispelling the effects of alcohol, protecting the liver, adjusting blood glucose, blood pressure and blood fat, and improving the skin and the like.

Methods and devices for reducing ventricle filling volume are disclosed. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to reduce ventricle filling volume or even blood pressure. When the heart is stimulated in a consistent way to reduce blood pressure, the cardiovascular system may over time adapt to the stimulation and revert back to the higher blood pressure. In some embodiments, the stimulation pattern may be configured to be inconsistent such that the adaptation response of the heart is reduced or even prevented. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to cause at least a portion of an atrial contraction to occur while the atrioventricular valve is closed. Such an atrial contraction may deposit less blood into the corresponding ventricle than when the atrioventricular valve is opened throughout an atrial contraction.

A method is provided for treating a dermatological condition in a patient. The method includes (a) measuring the intracellular water content of the patient to provide an initial intracellular water content measurement; (b) administering to the patient at least one active agent; (c) re-measuring the intracellular water content of the patient to provide a post-treatment intracellular water content measurement; and (d) repeating steps (b) and (c) until the post-treatment intracellular water content measurement is greater than the initial intracellular water content measurement. A method is also provided for treating other health-related conditions in a patient.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B—The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and / or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

Systems and methods for controlling blood pressure via electrical stimulation of the heart are disclosed. Embodiments may include at least two different stimulation patterns, each configured to reduce blood pressure to a different degree, and may alternate between stimulation patterns based on the need of a patient, for example, alternating between day and night or between periods of strenuous and light activity. Some embodiments may take advantage of a slow baroreflex response that occurs after treatment is stopped, suspending treatment for extended periods, and then resuming treatment before blood pressure levels reach pretreatment values. Embodiments may control blood pressure by controlling atrial pressure and atrial stretch.

The invention provides a method and system for transiently occluding a vein that is downstream of an organ such as the brain, where the occlusion increases blood pressure within the vein, and where the increased pressure stimulates a reflex that reduces entry of emboli into that organ.

The invention relates to health-preserving fungal tea and application thereof. The health-preserving fungal tea is prepared from the raw materials by weight fraction: 10 to 50 percent of edible or medicinal fungal fruit body and 50 to 90 percent of tea. The invention provides health-preserving fungal tea with simple and scientific matching and application thereof in anticancer aspect, so that the nutritive value and pharmacological action of single product are greatly improved. Through scientific matching, the actions of the active substances of the edible or medicinal fungal fruit body and tea are multiplied, so that the nutritive value and pharmacological action are greatly improved. By scientific matching, the fungal tea has unique mouthfeel and flavor, can serve as tea or tea bag to be directly soaked for drinking, can also be prepared into fungal tea beverage, oral liquid, polysaccharide capsule, tablets and the like, and has the efficacies of conditioning yin-yang balance of the functions of five internal organs, improving organism immunity, improving fatigue state, conditioning endocrine dyscrasia, improving blood pressure, blood sugar and blood fat, strengthening body, expelling toxin and protecting liver, preventing disease and radiation, reducing weight and fat, resisting tumor and aging and the like.

A method is provided, comprising: (1) making a transapical puncture into a left ventricle of the heart; (2) making a transseptal fenestration in the heart; (3) delivering a prosthetic valve via the transapical puncture and implanting the prosthetic valve at a mitral valve of the heart; and (4) subsequently to delivering the prosthetic valve and making the transseptal fenestration, closing the transapical puncture. Other embodiments are also described.

Provided are pharmaceutical compositions and methods of treatment or prophylaxis of certain neuropsychiatric conditions, in particular mood disorders. The compounds are of the general Formula I-V as described herein.

A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity / manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro / in vivo correlations.

A hemostatic device has a flexible band that can be wrapped around a hemostasis-requiring site of a limb, a securing portion that secures the band in a state where the band is wrapped around the limb, and an inflation portion that interlocks with the band, and that inflates when a fluid is injected. The inflation portion has a plurality of convex portions in a width direction orthogonal to a longitudinal direction of the band when the inflation portion inflates.

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.

An examination unit, which can be used especially in the area of acute and intensive diagnostics in hospitals (e.g. in emergency rooms, intensive care units, operating theaters etc.) or in ambulances is provided. The examination unit which at least has an ultrasonic device, patient monitor, ECG, ventilator and / or resuscitation device for monitoring the vital functions and / or for the immediate medical treatment of emergency patients with symptoms of acute cardiovascular disease, myocardial infarction, angina, apoplectic stroke, etc. The device furthermore according to the invention includes an integrated mini-laboratory analysis unit for the biochemical and / or cell-biology investigation of blood samples or tissue biopsies.

The invention relates to a novel quasi-physiological pulsating flow environment arterial blood vessel tissue engineering reactor. The reactor comprises a liquid storage device 27, a liquid driver 21 and a blood vessel tissue dynamic culture chamber 25 which are sequentially connected through a fluid pipeline to form a fluid circulation loop, and a pulsation generator 24, wherein the liquid driver21 drives a liquid culture medium to circularly flow; the pulsation generator 24 forms the pulsation of the circularly flowing liquid culture medium and comprises a pulsation chamber 241 which is a closed chamber with fixed volume, a closed piston 244 in the pulsation chamber 241, a linear steeping motor 243 and a pull rod 242; the pull rod connects the closed piston 244 with a driving shaft of the linear stepping motor 243; and the closed chamber is communicated with the fluid pipeline above the culture chamber 25.